Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Neoplasms
Interventions: ADH -1 (Exherin™); Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypertension
Interventions: Level of noise and environment (public vs private) while taking blood pressure measurement; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, High Blood Pressure, High Cholesterol, Type2 Diabetes, Heart Diseases
Interventions: Curcumin; Dietary Supplement
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
Interventions: Aspirin and/or Atorvastatin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Foot Ulcer, Diabetic
Interventions: Medical Food, Drink mix calorically similar to experimental product; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Brawley, California + 38 more

Conditions: Renal Insufficiency, Chronic Hypertension
Interventions: Spironolactone, Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 19 Years to 110 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Covina, California • Northridge, California + 24 more

Conditions: Chronic Kidney Disease
Interventions: Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo; Drug
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Kidney Disease, Liver Disease, Pancreas Disease
Interventions: RIPC by Inflation of Pneumatic Tourniquet; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Houma, Louisiana

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Tirofiban, Placebo; Drug
Lead sponsor: Dr David Hasan, M.D.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: ADHD
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Years to 18 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Arteriovenous Malformation
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 6 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke
Interventions: Community Health Worker (CHW), usual care and health education brochures every 4 months.; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions: Inclisiran, Evolocumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions: Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Embolism
Interventions: Intravascular Filter Device; Device
Lead sponsor: Rex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Burlingame, California • Newark, Delaware • Washington D.C., District of Columbia + 7 more

Conditions: Peripheral Artery Disease
Interventions: AFO to improve outcomes; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Hypertension, Coronary Artery Disease
Interventions: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 22,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Conservation of Red Cell Mass , Oxygen Supply and Demand in Cardiac Surgery

Determining Change In Blood Pressure Due to Environment and Loudness

Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome

Subclinical Cardiovascular Disease in Psoriatic Disease

Evaluation of a Medical Food for Chronic Wounds

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

Genetics of Arteriovenous Malformations

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Hispanic Secondary Stroke Prevention Initiative

Targeting Right Ventricle in Pulmonary Hypertension Gilead

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

RexMedical- Option* Vena Cava Filter IDE Study

Ankle-foot Orthoses for Peripheral Artery Disease

INVEST: INternational VErapamil SR Trandolapril STudy